A rare mitochondrial disease with a serious neurological impact.

What does TTC19 do?

TTC19 encodes a mitochondrial protein involved in the normal function and maintenance of respiratory-chain Complex III. Mechanistic work has linked TTC19 to quality control involving the Rieske protein UQCRFS1 and Complex III biogenesis.

What happens when TTC19 is disrupted?

Biallelic pathogenic variants can cause mitochondrial Complex III deficiency with variable neurological disease. Published reports include progressive ataxia, dystonia and other movement disorders, speech impairment, cognitive regression, peripheral neuropathy, loss of mobility and Leigh or Leigh-like neuroimaging features.

Why is TTC19 difficult to research?

TTC19 is ultra-rare. Small patient numbers, limited longitudinal data and relatively few established experimental models mean that collaboration and reusable research infrastructure are disproportionately important.

Why progress is still plausible

The disease has a defined genetic cause, a defined mitochondrial pathway and measurable biochemical consequences. Those give researchers concrete questions about functional rescue, disease models, downstream mechanisms and intervention testing.